HRP20240012T1 - Derivati 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)uree kao kcnq potencijatori - Google Patents
Derivati 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)uree kao kcnq potencijatori Download PDFInfo
- Publication number
- HRP20240012T1 HRP20240012T1 HRP20240012TT HRP20240012T HRP20240012T1 HR P20240012 T1 HRP20240012 T1 HR P20240012T1 HR P20240012T T HRP20240012T T HR P20240012TT HR P20240012 T HRP20240012 T HR P20240012T HR P20240012 T1 HRP20240012 T1 HR P20240012T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- image
- compound
- Prior art date
Links
- VDRSSRINXUQZRZ-UHFFFAOYSA-N [2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methylurea Chemical class FC(COC1=NC=CC(=C1)CNC(=O)N)(F)F VDRSSRINXUQZRZ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 206010001497 Agitation Diseases 0.000 claims 1
- 206010006542 Bulbar palsy Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- 201000002241 progressive bulbar palsy Diseases 0.000 claims 1
- 201000000196 pseudobulbar palsy Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962801716P | 2019-02-06 | 2019-02-06 | |
| US201962811038P | 2019-02-27 | 2019-02-27 | |
| PCT/US2020/016499 WO2020163268A1 (en) | 2019-02-06 | 2020-02-04 | 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators |
| EP20709409.5A EP3921030B1 (en) | 2019-02-06 | 2020-02-04 | 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240012T1 true HRP20240012T1 (hr) | 2024-03-29 |
Family
ID=69743945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240012TT HRP20240012T1 (hr) | 2019-02-06 | 2020-02-04 | Derivati 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)uree kao kcnq potencijatori |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US11208383B2 (https=) |
| EP (1) | EP3921030B1 (https=) |
| JP (2) | JP7451543B2 (https=) |
| KR (1) | KR102924196B1 (https=) |
| CN (1) | CN113692304B (https=) |
| AU (1) | AU2020218180B2 (https=) |
| BR (1) | BR112021015544A2 (https=) |
| DK (1) | DK3921030T3 (https=) |
| ES (1) | ES2968807T3 (https=) |
| FI (1) | FI3921030T3 (https=) |
| HR (1) | HRP20240012T1 (https=) |
| HU (1) | HUE064734T2 (https=) |
| IL (1) | IL285113B2 (https=) |
| LT (1) | LT3921030T (https=) |
| MX (1) | MX2021009396A (https=) |
| PL (1) | PL3921030T3 (https=) |
| PT (1) | PT3921030T (https=) |
| RS (1) | RS65040B1 (https=) |
| SA (1) | SA521422733B1 (https=) |
| SG (1) | SG11202108599SA (https=) |
| SI (1) | SI3921030T1 (https=) |
| SM (1) | SMT202400003T1 (https=) |
| WO (1) | WO2020163268A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE064734T2 (hu) * | 2019-02-06 | 2024-04-28 | Lilly Co Eli | 1-((2-(2,2,2-trifluoretoxi)piridin-4-il)metil)karbamid származékok mint KCNQ potenciátorok |
| CA3183298A1 (en) | 2020-06-25 | 2021-12-30 | Olivier Bezencon | Cyclobutyl-urea derivatives |
| TW202330471A (zh) * | 2021-09-30 | 2023-08-01 | 日商住友製藥股份有限公司 | 環丙醯胺衍生物 |
| WO2023091554A1 (en) * | 2021-11-19 | 2023-05-25 | Icagen, Llc | Novel heteroaryl-urea compounds as kv7.2 inhibitors |
| EP4433472A1 (en) | 2021-11-19 | 2024-09-25 | Icagen, LLC | Pyridine compounds as kv7.2 enhancers |
| JP2025502712A (ja) | 2021-12-22 | 2025-01-28 | アイカジェン・エルエルシー | シクロプロピル化合物 |
| EP4479377A1 (en) | 2022-02-15 | 2024-12-25 | Icagen, LLC | New bicyclopentane derivatives |
| IT202200024963A1 (it) * | 2022-12-05 | 2024-06-05 | Angelini Pharma S P A | Composti attivatori dei canali potassio Kv7.2/Kv7.3 |
| IT202200024948A1 (it) * | 2022-12-05 | 2024-06-05 | Angelini Pharma S P A | Composti attivatori dei canali potassio KV7.2/KV7.3 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL335905A1 (en) * | 1997-03-25 | 2000-05-22 | Astra Pharma Prod | Novel derivatives of pyridine and pharmaceutic compositions containing them |
| CN100345823C (zh) * | 2003-01-14 | 2007-10-31 | 赛特凯恩蒂克公司 | 化合物、组合物及方法 |
| KR20070030196A (ko) | 2004-04-13 | 2007-03-15 | 이카겐, 인코포레이티드 | 칼륨 이온 채널 조절제로서의 폴리시클릭 피리딘 |
| US7879839B2 (en) * | 2004-07-29 | 2011-02-01 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
| WO2010036316A1 (en) | 2008-09-24 | 2010-04-01 | Yangbo Feng | Urea and carbamate compounds and analogs as kinase inhibitors |
| KR20120031170A (ko) * | 2009-06-08 | 2012-03-30 | 길리애드 사이언시즈, 인코포레이티드 | 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물 |
| EP2681200A4 (en) * | 2011-03-03 | 2015-05-27 | Zalicus Pharmaceuticals Ltd | INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| CN103709097A (zh) | 2012-09-28 | 2014-04-09 | 中国科学院上海药物研究所 | 1,3-取代脲或硫脲化合物、其制备方法、药物组合物和应用 |
| RU2769607C2 (ru) | 2013-03-15 | 2022-04-04 | ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | N-ацил-N'-(пиридин-2-ил) карбамиды и их аналоги, проявляющие противораковую и антипролиферативную активность |
| EP3110794A1 (en) * | 2014-02-27 | 2017-01-04 | Merck Patent GmbH | Heterocyclic compounds as nav channel inhibitors and uses thereof |
| CA2965467A1 (en) * | 2014-10-24 | 2016-04-28 | Ono Pharmaceutical Co., Ltd. | Kcnq2-5 channel activator |
| EP3447045B9 (en) | 2016-04-22 | 2021-07-21 | ONO Pharmaceutical Co., Ltd. | 1-(1-hydroxy-2,3-dihydro-1h-inden-5-yl)-urea derivatives and related compounds kcnq 2-5 channel activators for treating dysuria |
| HUE064734T2 (hu) * | 2019-02-06 | 2024-04-28 | Lilly Co Eli | 1-((2-(2,2,2-trifluoretoxi)piridin-4-il)metil)karbamid származékok mint KCNQ potenciátorok |
-
2020
- 2020-02-04 HU HUE20709409A patent/HUE064734T2/hu unknown
- 2020-02-04 KR KR1020217028040A patent/KR102924196B1/ko active Active
- 2020-02-04 LT LTEPPCT/US2020/016499T patent/LT3921030T/lt unknown
- 2020-02-04 EP EP20709409.5A patent/EP3921030B1/en active Active
- 2020-02-04 HR HRP20240012TT patent/HRP20240012T1/hr unknown
- 2020-02-04 SG SG11202108599SA patent/SG11202108599SA/en unknown
- 2020-02-04 BR BR112021015544-9A patent/BR112021015544A2/pt unknown
- 2020-02-04 RS RS20240009A patent/RS65040B1/sr unknown
- 2020-02-04 MX MX2021009396A patent/MX2021009396A/es unknown
- 2020-02-04 PL PL20709409.5T patent/PL3921030T3/pl unknown
- 2020-02-04 JP JP2021546360A patent/JP7451543B2/ja active Active
- 2020-02-04 SI SI202030316T patent/SI3921030T1/sl unknown
- 2020-02-04 AU AU2020218180A patent/AU2020218180B2/en active Active
- 2020-02-04 SM SM20240003T patent/SMT202400003T1/it unknown
- 2020-02-04 IL IL285113A patent/IL285113B2/en unknown
- 2020-02-04 US US16/781,148 patent/US11208383B2/en active Active
- 2020-02-04 DK DK20709409.5T patent/DK3921030T3/da active
- 2020-02-04 WO PCT/US2020/016499 patent/WO2020163268A1/en not_active Ceased
- 2020-02-04 CN CN202080012797.0A patent/CN113692304B/zh active Active
- 2020-02-04 ES ES20709409T patent/ES2968807T3/es active Active
- 2020-02-04 FI FIEP20709409.5T patent/FI3921030T3/fi active
- 2020-02-04 PT PT207094095T patent/PT3921030T/pt unknown
-
2021
- 2021-08-05 SA SA521422733A patent/SA521422733B1/ar unknown
- 2021-11-19 US US17/531,000 patent/US11840516B2/en active Active
-
2023
- 2023-11-09 US US18/388,299 patent/US12344584B2/en active Active
-
2024
- 2024-03-06 JP JP2024033668A patent/JP2024063191A/ja not_active Withdrawn
-
2025
- 2025-05-27 US US19/219,238 patent/US20250282725A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240012T1 (hr) | Derivati 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)uree kao kcnq potencijatori | |
| HRP20220797T1 (hr) | Spojevi | |
| HRP20241590T1 (hr) | Supstituirani heterociklički fuzirani ciklički spoj, postupak njegove pripreme i njegova farmaceutska uporaba | |
| YU9194A (sh) | Derivati pipolo-piridina | |
| NZ590784A (en) | Pyrazolopyridine kinase inhibitors | |
| HRP20130738T1 (hr) | Postupak lijeäśenja ili profilakse | |
| ATE261448T1 (de) | Heteroaryl diazabicycloalkene, deren herstellung und verwendung | |
| MEP36508A (en) | Triazolopyrazine derivatives useful as anti-cancer agents | |
| HRP20211973T1 (hr) | Kinazolini kao inhibitori ionskih kalijskih kanala | |
| NO20062139L (no) | Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister | |
| HRP20140051T1 (hr) | Farmaceutski pripravci koji sadrže imidazokinolin(amine) i njihovi derivati prikladni za lokalno davanje | |
| PT1119567E (pt) | Derivados de quinazolina | |
| ES2165768A1 (es) | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. | |
| TW200718692A (en) | Dihydrobenzofuran derivatives and uses thereof | |
| ME01831B (me) | Kristalni oblici 2-tiazolil-4-hinolinil-oksi derivata, snažni hcv inhibitor | |
| SI3002283T1 (en) | Thiazole derivatives | |
| TW200720266A (en) | Benzodioxane and benzodioxolan derivatives and uses thereof | |
| JP2012507566A5 (https=) | ||
| HRP20211278T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| HRP20100180T1 (hr) | Novi spoj piridazina i njegova primjena | |
| JPH01224316A (ja) | 医薬製剤 | |
| FR2903107B1 (fr) | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique | |
| WO2002060423A3 (en) | Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists | |
| MX2009008463A (es) | Formulaciones biodisponibles de compuestos heterociclicos. | |
| ME02351B (me) | Derivati 2 -oxo- 1-imidazolidinil imidazotiadiazol |